The first pilot Phase 2 feasibility study of Aerosurf, developed by Dicovery Labs, showed promising results. Aerosurf is a aerosolized lung surfactant delivered using continuous positive airway pressure (nCPAP). It has the potential as a non-invasive method of surfactant replacement therapy to treat premature infants suffering from respiratory disorders including Respiratory Distress Syndrome (RDS), BPD, bronchiolitis, acute hypoxia, pneumonia, and transient tachypnea. RDS is a condition that is prevalent in premature infants, which is caused by a lack of lung surfactants than keeps air sacs from collapsing and therfore facilitate breathing.

Robert Segal MD, Senior Vice President and Chief Medical Officer further explains:

"Neonatologists have limited pharmacologic options to treat serious respiratory Diseases outside of RDS; many of these infants suffer significant morbidity and require costly treatments with prolonged hospital stays. No currently available surfactants have addressed these unmet needs. Aerosurf represents a novel therapeutic approach for the potential treatment of infants with various respiratory diseases.

For the next 30 days, audio webcast for shareholders and interested parties may be found here or here. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 9329269.

Photo Credits: Medline Plus